Activity Survey 2018

Patient and Transplant Numbers

Teams: 701
Participating countries: 50

1st allo / 1st auto HSCT

<table>
<thead>
<tr>
<th>Type</th>
<th>Allogeneic</th>
<th>Autologous</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st HSCT</td>
<td>18 483</td>
<td>24 418</td>
<td>42 901</td>
</tr>
<tr>
<td>Re/Additional</td>
<td>1 147</td>
<td>3 420</td>
<td>4 567</td>
</tr>
<tr>
<td>Total HSCT</td>
<td>19 630</td>
<td>27 838</td>
<td>47 468</td>
</tr>
</tbody>
</table>

Myeloablative HSCT 62%

Main Indications 1st HSCT

Myeloid malignancies 10 385 294 10 679
Lymphoid malignancies 5 369 21 949 27 318
Solid tumours 47 1 576 1 625
Bone marrow failure 954 5 959
Other non-malignant disorders 1 533 571 2 104
Other 195 21 216

Main trends in 2018

• Number of HSCT increase by 4.5% (7.4% allo and 2.6% auto)
• Continued increase in haploidentical (16%) and unrelated (5%) HSCT
• Increase in AML 1st CR, ALL, CML 1st cP, SAA in allo and AID in auto HSCT
• Cellular therapies: CAR T increase by 100% increase since 2017

Non HSCT Cellular therapies using manipulated or selected cells in 2018

Non HSCT Cellular therapies using manipulated or selected cells in 2018

<table>
<thead>
<tr>
<th>Family</th>
<th>Unrelated</th>
<th>Autologous</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM PB CB</td>
<td>BM PB BM PB CB BM PB CB BM PB CB</td>
<td></td>
</tr>
<tr>
<td>2 324</td>
<td>1 751</td>
<td>1 293</td>
</tr>
</tbody>
</table>

Main trends in 2018

• Number of HSCT increase by 4.5% (7.4% allo and 2.6% auto)
• Continued increase in haploidential (16%) and unrelated (5%) HSCT
• Increase in AML 1st CR, ALL, CML 1st cP, SAA in allo and AID in auto HSCT
• Cellular therapies: CAR T increase by 100% increase since 2017

Ebmt: JR, Passweg, H. Baldomero et al, Bone Marrow Transplantation, Feb 2020. Contact: helen.baldomero@usb.ch